IN BRIEF: Fusion Antibodies Surges On Virus Study Progress

Fri, 18th Sep 2020 21:16

Fusion Antibodies PLC - pharmaceutical company based in Belfast - Says proof-of-concept on Mammalian Antibody Library Discovery Platform, Covid-19 related research. Fusion Antibodies says "progress" being made on design of SARS-CoV-2 proteins as it looks to develop antigens to fight against virus. Stock more than doubled on Friday.

Current stock price: 222.67 pence

Year-to-date change: up sharply from 78.50p

By Eric Cunha; ericcunha@alliancenews.com

Related Shares

More News

23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

30 Apr 2024 19:54

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

15 Apr 2024 13:29

Fusion Antibodies inks commercial contract for OptiPhage library

(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibo...

27 Feb 2024 14:18

TRADING UPDATES: Sondrel wins USD23 million contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

27 Feb 2024 13:15

Fusion Antibodies gets first order under new services agreement

(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed w...